CLINICAL TRIALS PROFILE FOR NEUTREXIN

All Clinical Trials for NEUTREXIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002103 ↗	A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia	Completed	U.S. Bioscience	N/A	1969-12-31	To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in European patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).
NCT00002317 ↗	A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia	Completed	U.S. Bioscience	N/A	1969-12-31	To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in pediatric patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).
NCT00002434 ↗	A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)	Completed	U.S. Bioscience	N/A	1969-12-31	To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening toxicities to standard therapies (e.g., TMP/SMX or parenteral pentamidine).
NCT00003446 ↗	Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer	Completed	Grupo Oncologico Cooperativo del Sur	Phase 2	1997-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of trimetrexate glucuronate, fluorouracil, and leucovorin in treating patients with recurrent or metastatic colorectal cancer.

Clinical Trial Conditions for NEUTREXIN

Condition Name

Condition Name for NEUTREXIN
Intervention	Trials
HIV Infections	3
Pneumonia, Pneumocystis Carinii	3
Colorectal Cancer	1

Condition MeSH

Condition MeSH for NEUTREXIN
Intervention	Trials
Pneumonia	3
HIV Infections	3
Pneumonia, Pneumocystis	3
Colorectal Neoplasms	1

Clinical Trial Locations for NEUTREXIN

Trials by Country

Trials by Country for NEUTREXIN
Location	Trials
United States	3
Argentina	1

Trials by US State

Trials by US State for NEUTREXIN
Location	Trials
Pennsylvania	3

Clinical Trial Progress for NEUTREXIN

Clinical Trial Phase

Clinical Trial Phase for NEUTREXIN
Clinical Trial Phase	Trials
Phase 2	1
N/A	3

Clinical Trial Status

Clinical Trial Status for NEUTREXIN
Clinical Trial Phase	Trials
Completed	4

Clinical Trial Sponsors for NEUTREXIN

Sponsor Name

Sponsor Name for NEUTREXIN
Sponsor	Trials
U.S. Bioscience	3
Grupo Oncologico Cooperativo del Sur	1

Sponsor Type

Sponsor Type for NEUTREXIN
Sponsor	Trials
Industry	3
Other	1

NEUTREXIN Market Analysis and Financial Projection

Last updated: May 6, 2026

NEUTREXIN: Clinical Trials Update, Market Analysis, and Forward Projections

No complete, verifiable public record was found in the supplied context to identify NEUTREXIN’s active ingredient(s), sponsor, mechanism of action, regulatory status, or to locate trial identifiers (e.g., NCT numbers), study results, and endpoints. Without those anchor facts, a complete clinical-trials update and a defensible market projection cannot be produced from reliable sources.

Clinical trials update: not deliverable (no verifiable NEUTREXIN trial registry data in the provided context).
Market analysis and projection: not deliverable (no identifiable target label, country scope, pricing basis, or competitor set in the provided context).

What clinical-trials data exists for NEUTREXIN?

Not available in the provided context.

What is NEUTREXIN’s market and competitive landscape?

Not available in the provided context.

What forward market projection can be made for NEUTREXIN?

Not available in the provided context.

Key Takeaways

• No verified identification of NEUTREXIN (active ingredient, sponsor, indication, or trial IDs) is provided in the context, so no accurate clinical-trials update can be compiled.
• No verified indication, geography, pricing model, or comparator set is provided, so no credible market analysis or projection can be produced.

FAQs

1. What is NEUTREXIN?
   Not identifiable from the provided context.

2. Are there registered clinical trials for NEUTREXIN?
   Not identifiable from the provided context.

3. Has NEUTREXIN received any regulatory approvals?
   Not identifiable from the provided context.

4. What market size could NEUTREXIN address?
   Not determinable without the indication and geography in the provided context.

5. What is the likely competitive environment?
   Not determinable without the indication, MOA, and label definition in the provided context.

References

[1] No sources were provided in the prompt context for NEUTREXIN identification, clinical trials, or market data.